Next Article in Journal
Translocation Renal Cell Carcinoma: An Update on Clinicopathological and Molecular Features
Next Article in Special Issue
Exploring the Role of RGD-Recognizing Integrins in Cancer
Previous Article in Journal
Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
Previous Article in Special Issue
Involvement of the Integrin α1β1 in the Progression of Colorectal Cancer
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessFeature PaperReview
Cancers 2017, 9(9), 110; https://doi.org/10.3390/cancers9090110

Integrins as Therapeutic Targets: Successes and Cancers

1
Translational In Vivo Pharmacology, Translational Innovation Platform Oncology, Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany
2
Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
3
Translational and Biomarkers Research, Translational Innovation Platform Oncology, Merck KGaA, 64293 Darmstadt, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Helen M. Sheldrake
Received: 22 July 2017 / Revised: 11 August 2017 / Accepted: 14 August 2017 / Published: 23 August 2017
(This article belongs to the Special Issue Integrins in Cancer)
Full-Text   |   PDF [760 KB, uploaded 14 September 2017]   |  

Abstract

Integrins are transmembrane receptors that are central to the biology of many human pathologies. Classically mediating cell-extracellular matrix and cell-cell interaction, and with an emerging role as local activators of TGFβ, they influence cancer, fibrosis, thrombosis and inflammation. Their ligand binding and some regulatory sites are extracellular and sensitive to pharmacological intervention, as proven by the clinical success of seven drugs targeting them. The six drugs on the market in 2016 generated revenues of some US$3.5 billion, mainly from inhibitors of α4-series integrins. In this review we examine the current developments in integrin therapeutics, especially in cancer, and comment on the health economic implications of these developments. View Full-Text
Keywords: integrin; therapy; clinical trial; efficacy; health care economics integrin; therapy; clinical trial; efficacy; health care economics
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Raab-Westphal, S.; Marshall, J.F.; Goodman, S.L. Integrins as Therapeutic Targets: Successes and Cancers. Cancers 2017, 9, 110.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top